<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Regulatory T cells (T(reg) cells) are increased in context of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and their expansion can be correlated with higher disease burden and decreased survival </plain></SENT>
<SENT sid="1" pm="."><plain>Initially, interleukin 2 (IL-2) has been used as T-cell growth factor in clinical vaccination trials </plain></SENT>
<SENT sid="2" pm="."><plain>In murine models, however, a role of IL-2 in development, differentiation, homeostasis, and function of T(reg) cells was established </plain></SENT>
<SENT sid="3" pm="."><plain>In IL-2 treated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients a further T(reg)-cell expansion was described, yet, the mechanism of expansion is still elusive </plain></SENT>
<SENT sid="4" pm="."><plain>Here we report that functional T(reg) cells of a naïve phenotype--as determined by CCR7 and CD45RA expression--are significantly expanded in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment of 15 UICC <z:e sem="disease" ids="C0677950" disease_type="Neoplastic Process" abbrv="">stage IV colorectal cancer</z:e> patients with IL-2 in a phase I/II <z:chebi fb="7" ids="16670">peptide</z:chebi> vaccination trial further enlarges the already increased naïve T(reg)-cell pool </plain></SENT>
<SENT sid="6" pm="."><plain>Higher frequencies of T-cell receptor excision circles in naïve T(reg) cells indicate IL-2 dependent thymic generation of naïve T(reg) cells as a mechanism leading to increased frequencies of T(reg) cells post IL-2 treatment in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain>This finding could be confirmed in naïve murine T(reg) cells after IL-2 administration </plain></SENT>
<SENT sid="8" pm="."><plain>These results point to a more complex regulation of T(reg) cells in context of IL-2 administration </plain></SENT>
<SENT sid="9" pm="."><plain>Future strategies therefore might aim at combining IL-2 therapy with novel strategies to circumvent expansion and differentiation of naïve T(reg) cells </plain></SENT>
</text></document>